April 11, 2025 09:18 AM EDT
FDA+
Manufacturing

CD­MOs an­tic­i­pate in­spec­tion bot­tle­necks af­ter mass FDA fir­ings

Anna Brown

News Reporter

CD­MOs fear that FDA site in­spec­tions might slow down due to the mass staffing cuts at the fed­er­al health agen­cies.

While Pres­i­dent Don­ald Trump’s po­ten­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Ex­clu­sive: Topas claims suc­cess in ear­ly test of 'im­mune tol­er­ance' ther­a­py for celi­ac dis­ease

Ex­clu­sive: Deer­field se­cures $600M+ for third health­care ven­ture fund to seed new com­pa­nies

Ex­clu­sive: Ver­tex drops AAV gene ther­a­py re­search, tR­NA ther­a­py part­ner­ship

Ex­clu­sive: Af­ter FDA fir­ings, drug re­view­ers are asked to vol­un­teer for ad­min­is­tra­tive work

Drug­mak­ers ex­ploit can­cer’s ‘lethal­i­ties’ to make next class of tar­get­ed ther­a­pies, with first re­sults for ...

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times